The role of the PI3K pathway in colorectal cancer

Dionysios Papadatos-Pastos; Roy Rabbie; Paul Ross; Debashis Sarker

doi:10.1016/j.critrevonc.2014.12.006

The role of the PI3K pathway in colorectal cancer

Dionysios Papadatos-Pastos, Roy Rabbie, Paul Ross, Debashis Sarker

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

98 Citations (Scopus)

Abstract

In the last decade treatment for colorectal cancer (CRC) has evolved with the addition of contemporary chemotherapy drugs and targeted therapies. Despite this progress, our drug armamentarium is by no means complete and modern molecular biology techniques have led to the identification of a number of 'druggable' targets. One of the most important current drug targets is the phosphatidyl-inositol 3-kinase (PI3K) pathway, which is frequently deregulated in patients with CRC. In vitro and in vivo data strongly support the clinical development of compounds affecting signal transduction via the PI3K pathway. In this review we outline the role of PI3K in the development and progression of CRC and discuss data from current and ongoing clinical trials targeting this pathway. In addition we make suggestions toward the optimization of future research in order to derive the maximum benefit for patients with CRC.

Original language	English
Number of pages	13
Journal	Critical Reviews in Oncology/Hematology
DOIs	https://doi.org/10.1016/j.critrevonc.2014.12.006
Publication status	E-pub ahead of print - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2014.12.006

Cite this

@article{13ea5ea6c9bc4e69b8f1bf8aaebf00a4,

title = "The role of the PI3K pathway in colorectal cancer",

abstract = "In the last decade treatment for colorectal cancer (CRC) has evolved with the addition of contemporary chemotherapy drugs and targeted therapies. Despite this progress, our drug armamentarium is by no means complete and modern molecular biology techniques have led to the identification of a number of 'druggable' targets. One of the most important current drug targets is the phosphatidyl-inositol 3-kinase (PI3K) pathway, which is frequently deregulated in patients with CRC. In vitro and in vivo data strongly support the clinical development of compounds affecting signal transduction via the PI3K pathway. In this review we outline the role of PI3K in the development and progression of CRC and discuss data from current and ongoing clinical trials targeting this pathway. In addition we make suggestions toward the optimization of future research in order to derive the maximum benefit for patients with CRC.",

author = "Dionysios Papadatos-Pastos and Roy Rabbie and Paul Ross and Debashis Sarker",

year = "2014",

doi = "10.1016/j.critrevonc.2014.12.006",

language = "English",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The role of the PI3K pathway in colorectal cancer

AU - Papadatos-Pastos, Dionysios

AU - Rabbie, Roy

AU - Ross, Paul

AU - Sarker, Debashis

PY - 2014

Y1 - 2014

N2 - In the last decade treatment for colorectal cancer (CRC) has evolved with the addition of contemporary chemotherapy drugs and targeted therapies. Despite this progress, our drug armamentarium is by no means complete and modern molecular biology techniques have led to the identification of a number of 'druggable' targets. One of the most important current drug targets is the phosphatidyl-inositol 3-kinase (PI3K) pathway, which is frequently deregulated in patients with CRC. In vitro and in vivo data strongly support the clinical development of compounds affecting signal transduction via the PI3K pathway. In this review we outline the role of PI3K in the development and progression of CRC and discuss data from current and ongoing clinical trials targeting this pathway. In addition we make suggestions toward the optimization of future research in order to derive the maximum benefit for patients with CRC.

AB - In the last decade treatment for colorectal cancer (CRC) has evolved with the addition of contemporary chemotherapy drugs and targeted therapies. Despite this progress, our drug armamentarium is by no means complete and modern molecular biology techniques have led to the identification of a number of 'druggable' targets. One of the most important current drug targets is the phosphatidyl-inositol 3-kinase (PI3K) pathway, which is frequently deregulated in patients with CRC. In vitro and in vivo data strongly support the clinical development of compounds affecting signal transduction via the PI3K pathway. In this review we outline the role of PI3K in the development and progression of CRC and discuss data from current and ongoing clinical trials targeting this pathway. In addition we make suggestions toward the optimization of future research in order to derive the maximum benefit for patients with CRC.

U2 - 10.1016/j.critrevonc.2014.12.006

DO - 10.1016/j.critrevonc.2014.12.006

M3 - Article

C2 - 25591826

SN - 1040-8428

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

ER -

The role of the PI3K pathway in colorectal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this